PDF(Pubmed)
Abstract：
Introduction Lung cancer is the leading cause of oncological deaths worldwide. Various combined inflammatory indexes, such as the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) have shown associations with pretreatment survival prognosis in patients suffering of lung cancer with or without brain metastases. This study aimed to compare the average values of NLR, PLR, LMR, and SII in healthy patients, patients with lung cancer without any other metastases, and patients with lung cancer and brain metastases. Materials and methods In this prospective study, we have divided the patients into three groups: Group 1 included patients diagnosed with lung cancer and one or more brain metastases of lung cancer origin, Group 2 included patients diagnosed with lung cancer without known metastases, and Group 3 was the control group which included healthy subjects. Preoperative complete blood counts were extracted for all included patients and we calculated the values of SII, NLR, PLR, and LMR for each individual patient in each group. The next step was to calculate the average values of SII, NLR, PLR, and LMR for each group of patients and to identify the differences between groups. Results A total number of 228 patients were enrolled in the study. Group 1 included 67 patients with average values of SII = 2020.98, NLR = 7.25, PLR = 199.46, and LMR = 2.97. Group 2 included 88 patients with average values of SII = 1638.01, NLR = 4.58, PLR = 188.42, and LMR = 3.43. Group 3 included 73 subjects with the following average values of the inflammatory indexes: SII = 577.41, NLR = 2.34, PLR = 117.84, and LMR = 3.56. Conclusion We observed statistically significant differences in SII, NLR, and PLR among the three groups of patients, suggesting their potential role as prognostic markers. Furthermore, our analysis revealed significant correlations between inflammatory markers within lung cancer patients, highlighting their involvement in tumor microenvironment modulation. Our findings demonstrate an escalation in SII, NLR, and PLR values as the disease progresses. These parameters of inflammation and immune status are readily and cost-effectively, and repeatedly assessable in routine clinical practice.
摘要：
引言肺癌是全球肿瘤死亡的主要原因。各种联合炎症指标，如全身免疫炎症指数(SII)，中性粒细胞与淋巴细胞比率（NLR），淋巴细胞与单核细胞比率（LMR），血小板与淋巴细胞比值(PLR)与肺癌患者治疗前生存预后相关,无论有无脑转移.本研究旨在比较NLR的平均值，PLR,LMR,和健康患者的SII，没有任何其他转移的肺癌患者，肺癌和脑转移患者。材料和方法在这项前瞻性研究中，我们将患者分为三组：第一组包括诊断为肺癌和一个或多个肺癌起源的脑转移的患者，第2组包括诊断为肺癌但无已知转移的患者，第3组为对照组，包括健康受试者。提取所有纳入患者的术前全血计数，并计算SII值，NLR,PLR,和LMR为每组中的每个患者。下一步是计算SII的平均值，NLR,PLR,和LMR为每组患者，并找出组间差异。结果共纳入228例患者。第1组包括67例患者，平均SII=2020.98，NLR=7.25，PLR=199.46，LMR=2.97。第2组包括88例患者，平均SII=1638.01，NLR=4.58，PLR=188.42，LMR=3.43。第3组包括73名受试者，其炎症指数的平均值如下：SII=577.41，NLR=2.34，PLR=117.84，LMR=3.56。结论我们观察到SII的统计学差异，NLR,三组患者的PLR，提示它们作为预后标志物的潜在作用。此外，我们的分析揭示了肺癌患者体内炎症标志物之间的显著相关性，强调它们参与肿瘤微环境调节。我们的研究结果表明SII的升级，NLR,和PLR值随着疾病的进展。炎症和免疫状态的这些参数是容易和成本有效的，并在常规临床实践中反复评估。
